Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know

Alexander Villalobos; Mohamed M. Soliman; Bill S. Majdalany; David M. Schuster; James Galt; Zachary L. Bercu; Nima Kokabi

doi:10.1055/s-0040-1720954

Seminars in Interventional Radiology, Inhaltsverzeichnis

Semin intervent Radiol 2020; 37(05): 543-554
DOI: 10.1055/s-0040-1720954

Trainee Corner

Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know

Alexander Villalobos

¹Division of Interventional Radiology and Image Guided Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia

,

Mohamed M. Soliman

²Weill Cornell Medicine – Qatar School of Medicine, Education City, Al Luqta St, Ar-Rayyan, Qatar

,

Bill S. Majdalany

¹Division of Interventional Radiology and Image Guided Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia

,

David M. Schuster

³Division of Nuclear and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia

,

James Galt

³Division of Nuclear and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia

,

Zachary L. Bercu

¹Division of Interventional Radiology and Image Guided Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia

,

Nima Kokabi

¹Division of Interventional Radiology and Image Guided Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia

References
1 Ahmadzadehfar H, Biersack H-J, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 2010; 40 (02) 105-121
2 Kennedy A, Nag S, Salem R. et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68 (01) 13-23
3 Salem R, Lewandowski RJ, Sato KT. et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol 2007; 10 (01) 12-29
4 Wang S-C, Bester L, Burnes JP. et al. Clinical care and technical recommendations for ⁹⁰yttrium microsphere treatment of liver cancer. J Med Imaging Radiat Oncol 2010; 54 (03) 178-187
5 Salem R, Lewandowski RJ, Mulcahy MF. et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138 (01) 52-64
6 Lau WY, Lai ECH. Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability. Ann Surg Oncol 2007; 14 (12) 3301-3309
7 Murthy R, Habbu A, Salem R. Trans-arterial hepatic radioembolisation of yttrium-90 microspheres. Biomed Imaging Interv J 2006; 2 (03) e43
8 Tong AKT, Kao YH, Too CW, Chin KFW, Ng DCE, Chow PKH. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol 2016; 89 (1062): 20150943
9 Westcott MA, Coldwell DM, Liu DM, Zikria JF. The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres. Adv Radiat Oncol 2016; 1 (04) 351-364
10 Bastiaannet R, Kappadath SC, Kunnen B, Braat AJAT, Lam MGEH, de Jong HWAM. The physics of radioembolization. EJNMMI Phys 2018; 5 (01) 22
11 Wright CL, Zhang J, Tweedle MF, Knopp MV, Hall NC. Theranostic imaging of yttrium-90. BioMed Res Int 2015; 2015: 481279
12 TheraSphere Yttrium-90 Microspheres Package Insert, Boston Scientific Corporation. Accessed March 30, 2020 at: https://btgplc.com/BTG/media/TheraSphere-Documents/PDF/10093509-Rev8_English-searchable.pdf
13 SIR-Spheres Package Insert, SIRTeX Medical Limited. Accessed March 30, 2020 at: https://www.sirtex.com/media/155126/ssl-us-13.pdf
14 FDA, SIR-Spheres—Summary of Safety and Effectiveness Data. Accessed July 15, 2020 at: https://www.accessdata.fda.gov/cdrh_docs/pdf/P990065b.pdf
15 FDA, TheraSphere—Summary of Safety and Probable Benefit. Accessed July 15, 2020 at: https://www.accessdata.fda.gov/cdrh_docs/pdf/H980006B.pdf
16 Vente MAD, Wondergem M, van der Tweel I. et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009; 19 (04) 951-959
17 Devcic Z, Rosenberg J, Braat AJA. et al. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med 2014; 55 (09) 1404-1410
18 Kim SP, Cohalan C, Kopek N, Enger SA. A guide to ⁹⁰Y radioembolization and its dosimetry. Phys Med 2019; 68: 132-145
19 Salem R, Padia SA, Lam M. et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 2019; 46 (08) 1695-1704
20 Lewandowski RJ, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol 2006; 23 (01) 64-72
21 Snyder W, Ford M, Warner G, Watson S. Revised: estimates of absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. MIRD Pamphlet #5. 1978
22 Kao YH, Magsombol BM, Toh Y. et al. Personalized predictive lung dosimetry by technetium-99m macroaggregated albumin SPECT/CT for yttrium-90 radioembolization. EJNMMI Res 2014; 4 (01) 33
23 Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol 2019; 25 (31) 4360-4382
24 Strasberg SM, Belghiti J, Clavien P-A. et al. The Brisbane 2000 terminology of liver anatomy and resections. HPB (Oxford) 2000; 2 (03) 333-339
25 Germain T, Favelier S, Cercueil JP, Denys A, Krausé D, Guiu B. Liver segmentation: practical tips. Diagn Interv Imaging 2014; 95 (11) 1003-1016
26 Salem R, Thurston KG. Radioembolization with ⁹⁰yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006; 17 (08) 1251-1278
27 Gaba RC, Zivin SP, Dikopf MS. et al. Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting. Radiology 2014; 271 (02) 602-612
28 Xing M, Lahti S, Kokabi N, Schuster DM, Camacho JC, Kim HS. 90Y radioembolization lung shunt fraction in primary and metastatic liver cancer as a biomarker for survival. Clin Nucl Med 2016; 41 (01) 21-27
29 Kallini JR, Gabr A, Hickey R. et al. Indicators of lung shunt fraction determined by technetium-99 m macroaggregated albumin in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol 2017; 40 (08) 1213-1222
30 Olorunsola OG, Kohi MP, Behr SC. et al. Imaging predictors of elevated lung shunt fraction in patients being considered for yttrium-90 radioembolization. J Vasc Interv Radiol 2015; 26 (10) 1472-1478
31 Haste P, Tann M, Persohn S. et al. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission CT and posttreatment positron emission tomography/CT. J Vasc Interv Radiol 2017; 28 (05) 722-730.e1
32 Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur J Nucl Med Mol Imaging 2016; 43 (03) 559-575
33 Uliel L, Royal HD, Darcy MD, Zuckerman DA, Sharma A, Saad NE. From the angio suite to the γ-camera: vascular mapping and 99mTc-MAA hepatic perfusion imaging before liver radioembolization -- a comprehensive pictorial review. J Nucl Med 2012; 53 (11) 1736-1747
34 Allred JD, Niedbala J, Mikell JK, Owen D, Frey KA, Dewaraja YK. The value of ^99mTc-MAA SPECT/CT for lung shunt estimation in ⁹⁰Y radioembolization: a phantom and patient study. EJNMMI Res 2018; 8 (01) 50
35 Lopez B, Mahvash A, Lam MGEH, Kappadath SC. Calculation of lung mean dose and quantification of error for ⁹⁰ Y-microsphere radioembolization using ^99m Tc-MAA SPECT/CT and diagnostic chest CT. Med Phys 2019; 46 (09) 3929-3940
36 Boston Scientific, TheraSphere Package Insert. Accessed December 6, 2019 at: https://btgplc.com/BTG/media/TheraSphere-Documents/PDF/TheraSphere-Package-Insert_USA_Rev-14.pdf
37 Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997; 24 (03) 293-298
38 Leung TWT, Lau WY, Ho SKW. et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995; 33 (04) 919-924
39 Margolis LW, Phillips TL. Whole-lung irradiation for metastatic tumor. Radiology 1969; 93 (05) 1173-1179
40 Salem R, Parikh P, Atassi B. et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 2008; 31 (05) 431-438
41 Bilbao JI, Reiser MF. eds. Yttrium-90 microspheres for other liver metastases. In: Liver Radioembolization with 90Y Microspheres. Berlin: Springer-Verlag; 2014: 57-58
42 Committee on Medical Internal Radiation Dose (MIRD)—SNMMI. Accessed February 25, 2020 at: http://www.snmmi.org/AboutSNMMI/CommitteeContent.aspx?ItemNumber=12475&navItemNumber=763
43 Snyder W, Ford M, Warner G, Watson S. MIRD Pamphlet #11: S, Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. January 1975
44 Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med 2006; 47 (07) 1209-1211
45 Toohey RE, Stabin MG, Watson EE. The AAPM/RSNA physics tutorial for residents: internal radiation dosimetry: principles and applications. Radiographics 2000; 20 (02) 533-546 , quiz 531–532
46 Ho S, Lau WY, Leung TW. et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med 1996; 23 (08) 947-952
47 Gnesin S, Canetti L, Adib S. et al. Partition model-based 99mTc-MAA SPECT/CT predictive dosimetry compared with 90Y TOF PET/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: a quantitative agreement comparison. J Nucl Med 2016; 57 (11) 1672-1678
48 Wondergem M, Smits MLJ, Elschot M. et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med 2013; 54 (08) 1294-1301
49 Ilhan H, Goritschan A, Paprottka P. et al. Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in radioembolization of primary and secondary hepatic tumors. J Nucl Med 2015; 56 (11) 1654-1660
50 Tafti BA, Padia SA. Dosimetry of Y-90 microspheres utilizing Tc-99m SPECT and Y-90 PET. Semin Nucl Med 2019; 49 (03) 211-217
51 Vauthey JN, Abdalla EK, Doherty DA. et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl 2002; 8 (03) 233-240
52 Kao YH, Tan EH, Ng CE, Goh SW. Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. Ann Nucl Med 2011; 25 (07) 455-461
53 Riaz A, Gates VL, Atassi B. et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011; 79 (01) 163-171
54 Lau WY, Kennedy AS, Kim YH. et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 2012; 82 (01) 401-407
55 Malhotra A, Liu DM, Talenfeld AD. Radiation segmentectomy and radiation lobectomy: a practical review of techniques. Tech Vasc Interv Radiol 2019; 22 (02) 49-57
56 Vouche M, Habib A, Ward TJ. et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014; 60 (01) 192-201
57 Padia SA, Johnson GE, Horton KJ. et al. Segmental yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study. J Vasc Interv Radiol 2017; 28 (06) 777-785.e1
58 Gates VL, Hickey R, Marshall K. et al. Gastric injury from (90)Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?. Eur J Nucl Med Mol Imaging 2015; 42 (13) 2038-2044
59 Lewandowski RJ, Donahue L, Chokechanachaisakul A. et al. (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol 2016; 114 (01) 99-105
60 Vouche M, Lewandowski RJ, Atassi R. et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 2013; 59 (05) 1029-1036
61 Gaba RC, Lewandowski RJ, Kulik LM. et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 2009; 16 (06) 1587-1596
62 Siddiqi NH, Devlin PM. Radiation lobectomy-a minimally invasive treatment model for liver cancer: case report. J Vasc Interv Radiol 2009; 20 (05) 664-669
63 Palard X, Edeline J, Rolland Y. et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2018; 45 (03) 392-401
64 Ahmadzadehfar H, Meyer C, Ezziddin S. et al. Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study. Eur J Nucl Med Mol Imaging 2013; 40 (01) 80-90
65 Edeline J, Lenoir L, Boudjema K. et al. Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?. Ann Surg Oncol 2013; 20 (08) 2518-2525
66 Fernández-Ros N, Silva N, Bilbao JI. et al. Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. HPB (Oxford) 2014; 16 (03) 243-249
67 Garlipp B, de Baere T, Damm R. et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology 2014; 59 (05) 1864-1873
68 Teo JY, Goh BKP, Cheah FK. et al. Underlying liver disease influences volumetric changes in the spared hemiliver after selective internal radiation therapy with 90Y in patients with hepatocellular carcinoma. J Dig Dis 2014; 15 (08) 444-450
69 SIRTeX Medical SIR-Sphere Training Program: Physicians and Institutions: Page 35 of 111. SIRTEX Medical Limited
70 Gulec SA, Mesoloras G, Dezarn WA, McNeillie P, Kennedy AS. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med 2007; 5: 15
71 Birgin E, Rasbach E, Seyfried S. et al. Contralateral liver hypertrophy and oncological outcome following radioembolization with 90 y-microspheres: a systematic review. Cancers (Basel) 2020; 12 (02) E294
72 Cremonesi M, Chiesa C, Strigari L. et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol 2014; 4: 210
73 Vouche M, Degrez T, Bouazza F. et al. Sequential tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma. World J Hepatol 2017; 9 (36) 1372-1377
74 Teo JY, Allen Jr JC, Ng DC. et al. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. HPB (Oxford) 2016; 18 (01) 7-12
75 Toskich BB, Liu DM. Y90 radioembolization dosimetry: concepts for the interventional radiologist. Tech Vasc Interv Radiol 2019; 22 (02) 100-111
76 Abouchaleh N, Gabr A, Ali R. et al. 90 Y radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort. J Nucl Med 2018; 59 (07) 1042-1048
77 Garin E, Rolland Y, Edeline J. et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med 2015; 56 (03) 339-346
78 Garin E, Rolland Y, Edeline J. ⁹⁰Y-loaded microsphere SIRT of HCC patients with portal vein thrombosis: high clinical impact of 99mTc-MAA SPECT/CT-based dosimetry. Semin Nucl Med 2019; 49 (03) 218-226
79 Somma F, Stoia V, Serra N, D'Angelo R, Gatta G, Fiore F. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: the impact of portal vein thrombosis on survival. PLoS One 2019; 14 (05) e0216935
80 Sangro B, Gil-Alzugaray B, Rodriguez J. et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112 (07) 1538-1546
81 Riaz A, Lewandowski RJ, Kulik LM. et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009; 20 (09) 1121-1130 , quiz 1131
82 Lam MGEH, Louie JD, Iagaru AH, Goris ML, Sze DY. Safety of repeated yttrium-90 radioembolization. Cardiovasc Intervent Radiol 2013; 36 (05) 1320-1328
83 Elsayed M, Ermentrout RM, Sethi I. et al. Incidence of radioembolization-induced liver disease and liver toxicity following repeat 90Y-radioembolization: outcomes at a large tertiary care center. Clin Nucl Med 2020; 45 (02) 100-104
84 McNeillie P, Kennedy AS, Dezarn W, Sailer SL, England M, Overton C. Liver tolerance to repeat 90Y-microsphere radioembolization. J Med Device 2008; 2 (02) 027539
85 Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol 2014; 4: 198
86 Gil-Alzugaray B, Chopitea A, Iñarrairaegui M. et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013; 57 (03) 1078-1087
87 Piana PM, Gonsalves CF, Sato T. et al. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. J Vasc Interv Radiol 2011; 22 (10) 1373-1379
88 Gaba RC. Planning arteriography for yttrium-90 microsphere radioembolization. Semin Intervent Radiol 2015; 32 (04) 428-438
89 Vesselle G, Petit I, Boucebci S, Rocher T, Velasco S, Tasu JP. Radioembolization with yttrium-90 microspheres work up: practical approach and literature review. Diagn Interv Imaging 2015; 96 (06) 547-562
90 Lopera JE. The Amplatzer vascular plug: review of evolution and current applications. Semin Intervent Radiol 2015; 32 (04) 356-369
91 Meek J, Fletcher S, Gauss CH, Bezold S, Borja-Cacho D, Meek M. Temporary balloon occlusion for hepatic arterial flow redistribution during yttrium-90 radioembolization. J Vasc Interv Radiol 2019; 30 (08) 1201-1206
92 Sirtex - FLEXdose Delivery Program. Accessed April 13, 2020 at: https://www.sirtex.com/us/clinicians/flexdose-delivery-program/
93 TheraSphere™ Y-90 Glass Microspheres - TheraSphere-iDOC - Boston Scientific. Accessed April 13, 2020 at: https://www.bostonscientific.com/en-US/products/cancer-therapies/therasphere-y90-glass-microspheres/ordering-information/therasphere-idoc.html
94 Walrand S, Hesse M, Chiesa C, Lhommel R, Jamar F. The low hepatic toxicity per Gray of 90Y glass microspheres is linked to their transport in the arterial tree favoring a nonuniform trapping as observed in posttherapy PET imaging. J Nucl Med 2014; 55 (01) 135-140
95 Yang Y, Si T. Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Biol Med 2018; 15 (03) 299-310